Pipeline

Vaccinia Program

Program
Oncolytic Virotherapy (RIG-1250)
Therapeutics Area(s)

Solid Tumors

Product Rights
Research
Non-clinic (POC)
IND-Enabling

Adenovirus Program

Program
Oncolytic Virotherapy(RIG-2130)
Therapeutics Area(s)

Solid Tumors

Product Rights
Research
Non-clinic (POC)
IND-Enabling

Adenovirus Program

Program
Gene Therapy
Therapeutics Area(s)

Undisclosed GeneticDiseases

Product Rights
Research
Non-clinic (POC)
IND-Enabling
Program
Therapeutics Area(s)
Research
Non-clinic (POC)
IND-Enabling
Product Rights

Vaccinia Program

Oncolytic Virotherapy
(RIG-1250)

Solid Tumors

Adenovirus Program

Oncolytic Virotherapy
(RIG-2130)

Solid Tumors

Gene Therapy

Undisclosed Genetic
Diseases

Oncolytic Virotherapy (RIG-1250)

Solid Tumors

Oncolytic Virotherapy
(RIG-2130)

Solid Tumors

mRNA

PCD gene 3

Inhaled

Gene Therapy

In vivo CAR-T

Gene Therapy

Undisclosed Genetic Diseases

Undisclosed Partner

CNS

Various

Multiple

Undisclosed

Intrathecal

Our Programs

Learn More about our Programs

Vaccinia Program

RIG-1250 is an engineered vaccinia virus armed with multiple immunostimulatory transgenes. VV does not have a specific receptor for cell entry allowing it to infect a wide range of cells and has a natural tropism to cancer cells.

Adenovirus Program

We have developed a "gutless" adenovirus construct devoid of any viral genes, capable of delivering large transgenes (up to 36 kB) to a range of target tissues and organs.

Explore our Platform Technology

ReIGNITE is harnessing directed evolution for the precise in vivo delivery of oncolytic immunotherapies and gene therapies.